Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2001-01-04
2002-08-27
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S465000, C424S468000, C424S451000, C424S452000
Reexamination Certificate
active
06440459
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a paroxetine maleate polymorph and to pharmaceutical formulations containing it; it also relates to the use and to a process for the preparation thereof. This polymorph is crystalline and is used as stable active principle in the preparation of pharmaceutical formulations indicated for disorders deriving from dysfunction of the central nervous system.
PRIOR ART REFERENCE
Paroxetine maleate, corresponding chemically to the (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine acid maleate of formula
is described, together with a process for the preparation thereof, in Example 2 of U.S. Pat. No. 4,007,196 and in the same example of the corresponding Spanish patent of introduction ES-A-504997.
It is well known that paroxetine and the pharmaceutically acceptable salts thereof have a recognized activity as agents for the treatment of disorders related with dysfunction of the central nervous system, mainly, although not only, as antidepressants.
Owing to its poor handling properties, paroxetine base, is rather unsuitable for the preparation of pharmaceutical formulations and, up to date, has only been able to be used in practice in pharmaceutical formulations, as a paroxetine salt, namely, paroxetine hydrochloride. Thus, subsequent to the above mentioned U.S. patent, priority of which dates from 1974, the present inventors are unaware of the description or public use of paroxetine maleate in pharmaceutical formulations having commercial significance. On the contrary, there are numerous published patents and patent applications propounding the pharmaceutical use of paroxetine hydrochloride, both amorphous and in the non-hydrated and semi-hydrated crystalline forms thereof, among which there may be cited as examples EP-A-0188081, EP-A-0223403, WO-A-96/24595, EP-A-0810224 and U.S. Pat. No. 5,672,612, and there are numerous academic and scientific publications on the matter.
This is due to the fact that paroxetine maleate previously described in the documents U.S. Pat. No. 4,007,196 and ES-A-504997 is prepared in a form that will, hereinafter, be called Form A, which is substantially chemically unstable, which means that it undergoes degradation with time, which is a serious problem for any pharmaceutical formulation containing it.
There still exists, therefore, the need to having access to new pharmaceutically acceptable salts of paroxetine which may conveniently be used as an alternative to the different types of hydrochlorides described.
SUMMARY OF THE INVENTION
The object of the present invention is a new crystalline polymorph of paroxetine maleate, hereinafter called Form B, characterized in that it shows, substantially, the X-ray diffraction data given below in Table 1.
This Form B has superior stability properties; the invention also relates to a process for the preparation thereof.
Also object of the present invention are the pharmaceutical formulations containing the said new paroxetine maleate polymorph and the use of said polymorph in the manufacture of drugs against disorders related with dysfunction of the central nervous system.
REFERENCES:
patent: 4007196 (1977-02-01), Christensen et al.
patent: 5672612 (1997-09-01), Ronsen et al.
patent: 2187128 (1998-04-01), None
patent: 0 188 081 (1986-07-01), None
patent: 0 223 403 (1987-05-01), None
patent: 0 269 303 (1988-06-01), None
patent: 0 810 224 (1997-12-01), None
patent: WO 96/24595 (1996-08-01), None
Bosch Lladó Jordi
Molins Grau Elias
Onrubia Miguel Maria del Carmen
Stampa Diez del Corral Alberto
Bennett Rachel M.
Medichem S.A.
Scully Scott Murphy & Presser
LandOfFree
Paroxetine maleate polymorph and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Paroxetine maleate polymorph and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paroxetine maleate polymorph and pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2893025